Sevoflurane vs propofol in high risk cardiac surgery: design of the randomized trial “Sevo-Aifa”
1,Department of Anesthesia and Intensive Care Istituto Scientifico San Raffaele
2Cardiothoracic Department, Azienda Ospedaliera Universitaria Pisana
3Department of Anesthesia and Intensive Care, Università Vita-Salute San Raffaele
4,Department of Cardiac Anesthesia Padova
5Dipartimento di Scienze Anestesiologiche Medicina Critica e Terapia del Dolore, Università degli Studi “La Sapienza”
DOI: 10.22514/SV61.042011.6 Vol.6,Issue 1,May 2011 pp.36-40
Published: 02 May 2011
Objective. Recent evidence indicates that volatile anesthetics improve post-ischemic recovery. In a meta-analysis of 22 randomized studies, the use of volatile anesthetics was associated with significant reduction in myocardial infarction and mortality. All the studies in this meta-analysis included low risk patients undergoing isolated procedures (mostly isolated coronary artery bypass grafting). We want to confirm the cardioprotective effects of volatile anesthetics, in cardiac surgery, as indicated by a reduced intensive care unit stay and/or death in a high risk population of patients, undergoing combined valvular and coronary procedures.
Methods. Four centres will randomize 200 patients to receive either total intravenous anesthesia with propofol or anesthesia with sevoflurane. All patients will receive a standard average dose of opiates. Perioperative management will be otherwise identical and standardized. Transfer out of the intensive care unit will follow standard criteria.
Results. Reduced cardiac damage will probably translate into better tissue perfusion and faster recovery, as documented by a reduced intensive care unit stay. The study is powered to detect a reduction in the composite end point of prolonged intensive care unit stay (>2days) and/or death from 60% to 40%.
Conclusions. This will be the first multicentre randomized controlled trial comparing the effects of volatile anesthetics and total intravenous anesthesia in high risk patients undergoing cardiac procedures. Our trial should help clarify whether or not volatile agents should be recommended in high risk patients undergoing cardiac surgery.
anesthetic gases, cardiac surgical procedures, myocardium pro-tection, sevoflurane, cardiac anesthe-sia, intensive care, volatile agents
GIOVANNI LANDONI,FABIO GUARRACINO,RUBIA BALDASSARRI,CLAUDIA CARIELLO ,CHIARA GERLI,GRETA FANO,FRANCESCO DE SIMONE,LUIGI CASSARÀ,ELENA FRATI,DEMETRIO PITTARELLO,LUIGI TRITAPEPE,ALBERTO ZANGRILLO. Sevoflurane vs propofol in high risk cardiac surgery: design of the randomized trial “Sevo-Aifa”. Signa Vitae. 2011. 6(1);36-40.
1. Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, et al. American College of Cardiology; American Heart Association. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004;110:e340-437.
2. Slogoff S, Keats AS. Randomized trial of primary anesthetic agents on outcome of coronary artery bypass operations. Anesthesiology 1989;70:179-88.
3. Tuman KJ, McCarthy RJ, Spiess BD, DaValle M, Dabir R, Ivankovich AD. Does choice of anesthetic agent significantly affect outcome after coronary artery surgery? Anesthesiology 1989;70:189-98.
4. De Hert SG, Turani F, Mathur S, Stowe DF. Cardioprotection with volatile anesthetics: mechanisms and clinical implications. Anesth Analg 2005;100:1584-93.
5. Chiari P, Bouvet F, Piriou V. Anaesthetic-induced myocardial preconditioning: fundamental basis and clinical implications. Ann Fr Anesth Reanim 2005;24:383-96.
6. De Hert SG. Volatile anesthetics and cardiac function. Semin Cardiothorac Vasc Anesth 2006;10:33-42.
7. De Hert SG. The concept of anaesthetic-induced cardioprotection: clinical relevance. Best Pract Res Clin Anaesthesiol 2005;19:445-59.
8. Landoni G, Bignami E, Oliviero F, Zangrillo A. Halogenated anaesthetics and cardiac protection in cardiac and non-cardiac anaesthesia. Ann Card Anaesth 2009;12:4-9.
9. Landoni G, Fochi O, Torri G. Cardiac protection by volatile anaesthetics: a review. Curr Vasc Pharmacol 2008;6:108-11.
10. Landoni G, Biondi-Zoccai GG, Zangrillo A, Bignami E, D’Avolio S, Marchetti C, et al. Desflurane and sevoflurane in cardiac surgery: a meta-analysis of randomized clinical trials. J Cardiothorac Vasc Anesth 2007;21:502-11.
11. Tritapepe L, Landoni G, Guarracino F, Pompei F, Crivellari M, Maselli D, et al. Cardiac protection by volatile anaesthetics: a multicentre randomized controlled study in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Eur J Anaesthesiol 2007;24:323-31.
12. De Hert SG, Van der Linden PJ, Cromheecke S, Meeus R, ten Broecke PW, De Blier IG, et al. Choice of primary anesthetic regimen can influence intensive care unit length of stay after coronary surgery with cardiopulmonary bypass. Anesthesiology 2004;101:9-20.
13. De Hert SG, Van der Linden PJ, Cromheecke S, Meeus R, Nelis A, Van Reeth V, et al. Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration. Anesthesiology 2004;101:299-310.
14. Guarracino F, Landoni G, Tritapepe L, Pompei F, Leoni A, Aletti G, et al. Myocardial damage prevented by volatile anesthetics: a multicenter randomized controlled study. J Cardiothorac Vasc Anesth 2006;20:477-83.
15. Conzen PF, Fischer S, Detter C, Peter K. Sevoflurane provides greater protection of the myocardium than propofol in patients undergoing off-pump coronary artery bypass surgery. Anesthesiology 2003;99:826-33.
16. Bein B, Renner J, Caliebe D, Scholz J, Paris A, Fraund S, et al. Sevoflurane but not propofol preserves myocardial function during minimally invasive direct coronary artery bypass surgery. Anesth Analg 2005;100:610-6.
17. Bignami E, Landoni G, Crescenzi G, Gonfalini M, Bruno G, Pappalardo F, et al. Role of cardiac biomarkers (troponin I and CK-MB) as predictors of quality of life and long-term outcome after cardiac surgery. Ann Card Anaesth 2009;12:22-6.
18. Landoni G, Calabrò MG, Marchetti C, Bignami E, Scandroglio AM, Dedola E, et al. Desflurane versus propofol in patients undergoing mitral valve surgery. J Cardiothorac Vasc Anesth 2007;21:672-7.
19. Cromheecke S, Pepermans V, Hendrickx E, Lorsomradee S, Ten Broecke PW, Stockman BA, et al. Cardioprotective properties of sevoflu-rane in patients undergoing aortic valve replacement with cardiopulmonary bypass. Anesth Analg 2006;103:289-96.
20. Kato R, Foex P. Myocardial protection by anesthetic agents against ischemia-reperfusion injury: An update for anesthesiologists. Can J Anaesth 2002;49:777-91.
21. Landoni G, Fochi O, Bignami E, De Simone F, Zangrillo A. Volatile anesthetics for periprocedural cardiac protection. A review. Minerva Cardioangiol 2008;56:429-34.
22. Landoni G, Fochi O, Tritapepe L, Guarracino F, Belloni I, Bignami E, et al. Cardiac protection by volatile anesthetics. A review. Minerva Anestesiol 2009;75:269-73.
23. Bignami E, Biondi-Zoccai G, Landoni G, Fochi O, Testa V, Sheiban I, et al. Volatile Anesthetics Reduce Mortality in Cardiac Surgery. J Cardiothorac Vasc Anesth 2009;23:594-9.
24. Landoni G, Augoustides JG, Guarracino F, Santini F, Ponschab M, Pasero D, et al. Mortality reduction in cardiac anesthesia and inten-sive care: results of the first International Consensus Conference. Hsr proceedings in intensive care and cardiovascular anesthesia. 2011;3:9-19.
25. Landoni G, Fochi O, Bignami E, Calabrò MG, D’Arpa MC, Moizo E, et al. Cardiac protection by volatile anesthetics in non-cardiac surgery? A meta-analysis of randomized controlled studies on clinically relevant endpoints. Hsr proceedings in intensive care and cardiovascular anesthesia. 2011;2:34-43.
26. Landoni G, Zangrillo A, Fochi O, Maj G, Scandroglio AM, Morelli A, et al. Cardiac protection with volatile anesthetics in stenting procedures. J Cardiothorac Vasc Anesth 2008;22:543-7.
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.
IndexCopernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.
Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.
Scopus: CiteScore 0.5(2019) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.
Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.